© Reuters.
LAWRENCEVILLE, N.J. – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotech firm, announced Monday that Dr. Corinne Le Goff has resigned as President and CEO, effective March 15, 2024. Executive Chairman Michael H. Tardugno will lead the company’s day-to-day operations while the search for a new CEO is conducted.
Dr. Le Goff’s departure is to pursue another business opportunity. Tardugno, who served as CEO prior to Dr. Le Goff, will continue overseeing the company’s strategic direction. “IMUNON has the bench strength more than sufficient to advance our two platform technologies,” Tardugno stated, affirming that the development strategy and timelines for key programs are on track.
The company is preparing for a Phase 1 study of its COVID-19 booster vaccine, IMNN-101, and expects to release topline data from the OVATION 2 Study with IMNN-001 for advanced ovarian cancer this summer.
IMUNON specializes in non-viral DNA-mediated immunotherapy and vaccines, with a focus on generating safe and durable responses in various diseases. Its lead clinical program, IMNN-001, is an immunotherapy for advanced ovarian cancer, while other preclinical studies target COVID-19, LASSA virus, and melanoma.
The company will discuss its fourth quarter and full year 2023 financial results and provide corporate updates during an investment community conference call on March 28, 2024.
This announcement is based on a press release statement from IMUNON.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
